Novartis projects 5% constant-currency net sales CAGR for 2026-2031
NVS•Novartis forecasts 5% compound annual net sales growth at constant currencies from 2026 to 2031 and expects its core operating income margin to return to 40% or more by 2029. It raised peak sales forecasts for Kesimpta to $8 billion and Scemblix and Leqvio to $5 billion each.
1. Growth and product forecasts
Novartis projects 5% compound annual net sales growth at constant currencies for 2026-2031, with its core operating income margin returning to 40% or more by 2029. It raised Kesimpta’s peak sales guidance to $8 billion from $6 billion, and Scemblix and Leqvio forecasts to $5 billion each from $4 billion. Nine marketed assets now have peak sales potential of $3 billion to $10 billion, following an upgrade of Rhapsido/remibrutinib to $8 billion. Novartis expects more than 35 potentially submission-enabling readouts through 2031 to support sustained mid-single-digit sales growth over the long term.




